| A Cross-Laboratory Comparison of Caco-2 and Human Intestinal Drug Transporter Protein Abundances MD Harwood, B Achour, Y Courbebaisse, MR Russell, S Neuhoff, ... DMDG and GMP Joint Meeting, 2014 | | 2014 |
| A Dynamic Physiologically-Based Pharmacokinetic (PBPK) Model to Predict the Disposition of Rosuvastatin in Human and the Extent of Drug-Drug Interactions A Rostami-Hochaghan, F Bajot, S Neuhoff, Z Barter, K Rowland-Yeo, ... AAPS Annual Meeting and Exposition, Chicago, IL, USA, 2012 | | 2012 |
| A guide to developing population files for physiologically‐based pharmacokinetic modeling in the Simcyp Simulator L Curry, S Alrubia, FY Bois, R Clayton, E El‐Khateeb, TN Johnson, ... CPT: Pharmacometrics & Systems Pharmacology, 2024 | | 2024 |
| A laboratory-specific scaling factor to predict the in vivo human clearance of aldehyde oxidase substrates MDS Mendes, AL Orton, HE Humphries, B Jones, I Gardner, S Neuhoff, ... Drug Metabolism and Disposition 48 (11), 1231-1238, 2020 | 12 | 2020 |
| A mechanistic framework for in vitro–in vivo extrapolation of liver membrane transporters: prediction of drug–drug interaction between rosuvastatin and cyclosporine M Jamei, F Bajot, S Neuhoff, Z Barter, J Yang, A Rostami-Hodjegan, ... Clinical pharmacokinetics 53, 73-87, 2014 | 182 | 2014 |
| A MECHANISTIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL TO PREDICT THE PHARMACOKINETICS OF R/S-OXAZEPAM AFTER ORAL DOSING DB Turner, D Pade, M Jamei, S Neuhoff Drug Metabolism Reviews 47, 221-222, 2015 | | 2015 |
| A physiologically based pharmacokinetic modeling approach for predicting the exposure of irinotecan and its active metabolite (SN-38) in cancer patients KZ Denic, S Neuhoff, J Reid, R Kudget MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| A Physiologically-Based Pharmacokinetic Model to Predict the Disposition of Topotecan in Transporter Wild Type and Knock-Out Mice DS Pade, S Neuhoff, DB Turner, M Jamei, A Rostami-Hodjegan | | |
| A user-friendly physiologically-based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain A Rostami-Hochaghan, G Lu, S Neuhoff, M Jamei, A Rostami-Hodjegan 26th JSSX Annual Meeting, Hiroshima, Japan, 2011 | | 2011 |
| Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro–in vivo extrapolation of oral drug absorption MD Harwood, S Neuhoff, GL Carlson, G Warhurst, A Rostami‐Hodjegan Biopharmaceutics & drug disposition 34 (1), 2-28, 2013 | 124 | 2013 |
| Abstract A140: A physiologically based pharmacokinetic modeling approach for predicting the exposure of irinotecan and its active metabolite (SN-38) in cancer patients KZ Denic, S Neuhoff, J Reid, R Kudget Molecular Cancer Therapeutics 22 (12_Supplement), A140-A140, 2023 | | 2023 |
| Abundance & relative segmental expression of intestinal transporters in caucasians: A meta-analysis MD Harwood, M Zhang, S Pathak, I Gardner, S Neuhoff Drug Metabolism and Pharmacokinetics 33 (1), S88-S89, 2018 | | 2018 |
| Abundance of hepatic transporters in caucasians: a meta-analysis AE Riedmaier, H Burt, K Gill, M Harwood, S Neuhoff DRUG METABOLISM REVIEWS 48, 140-140, 2016 | | 2016 |
| Abundance of hepatic transporters in Caucasians: a meta-analysis HJ Burt, AE Riedmaier, MD Harwood, HK Crewe, KL Gill, S Neuhoff Drug metabolism and disposition 44 (10), 1550-1561, 2016 | 84 | 2016 |
| Acamprosate has no impact on the permeability of paracellular markers across Caco-2 cells I Antonescu, B Steffansen, S Neuhoff 6th FIP Pharmaceutical Sciences World Congress 2017: Future Medicines For …, 2017 | | 2017 |
| Acamprosate is a substrate of the human organic anion transporter (OAT) 1 without OAT3 inhibitory properties: implications for renal acamprosate secretion and drug–drug … IE Antonescu, M Karlgren, ML Pedersen, I Simoff, CAS Bergström, ... Pharmaceutics 12 (4), 390, 2020 | 8 | 2020 |
| Acamprosate is an inhibitor of the renal organic anion transporter (OAT) 1 IE Antonescu, M Karlgren, M Pedersen, I Simoff, C Bergström, S Neuhoff, ... | | 2019 |
| Acamprosate permeability across Caco-2 cell monolayer is predominantly paracellular IE Antonescu, S Neuhoff, X Fretté, CU Nielsen, B Steffansen Northern Pharma Network Meeting & POP Kick off-Meeting Conference 2018, Odense, 2018 | | 2018 |
| Accounting for transporters in renal clearance: towards a mechanistic kidney model (Mech KiM) S Neuhoff, L Gaohua, H Burt, M Jamei, L Li, GT Tucker, ... Transporters in drug development: discovery, optimization, clinical study …, 2013 | 78 | 2013 |
| Advantages and disadvantages of using bovine serum albumin and/or Cremophor EL as extracellular additives during transport studies of lipophilic compounds across Caco-2 monolayers S Neuhoff, P Artursson, AL Ungell Journal of drug delivery science and technology 17 (4), 259-266, 2007 | 6 | 2007 |
Amin Rostami-HodjeganProfessor of Systems Pharmacology, University of Manchester, UK在 manchester.ac.uk 的电子邮件经过验证
